March 2025 in “Nature Communications” NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
October 2024 in “Current Issues in Molecular Biology” Platycladus orientalis leaf extract helps hair grow by activating certain proteins.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
March 2024 in “Nutrients” Gynostemma pentaphyllum and its component damulin B could help hair grow by activating certain cell pathways.
July 2023 in “IntechOpen eBooks” New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
June 2023 in “Current Issues in Molecular Biology” DN106212, an extract from a plant, is better at promoting hair growth than other tested substances by affecting hair growth factors and follicle development.
December 2021 in “Figshare” New therapies like JAK inhibitors and stem cells show promise for treating vitiligo.
April 2019 in “Journal of Investigative Dermatology” Y27632 increases cell growth through EGFR signaling, not ROCK1/2.
April 2026 in “The Journal of Dermatology” Vitiligo patients have higher risks of autoimmune diseases, infections, and skin cancer.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
September 2025 in “Value in Health”
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
April 2025 in “Pharmaceutics” Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
July 2024 in “JAAD Case Reports” Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.
research Hair
May 2024 in “Australasian Journal of Dermatology” Alopecia areata causes significant emotional and social challenges, especially with more hair loss.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
May 2022 in “Journal of the Dermatology Nurses' Association” The convention highlighted the importance of comprehensive patient care and early diagnosis in dermatology.
January 2022 in “Faculty of 1000 Research Ltd” Understanding molecular mediators can improve skin healing treatments.
8 citations
,
July 2020 in “Clinical, cosmetic and investigational dermatology” Excessive sun protection might cause frontal fibrosing alopecia by disrupting skin immune balance.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
3 citations
,
June 2023 in “Journal of dermatological treatment” Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.